Promising Biotech Stocks To Add to Your Watchlist – February 04th

Danaher, AbbVie, Moderna, Thermo Fisher Scientific, Fabrinet, Vertex Pharmaceuticals, and Illumina are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks refer to publicly traded companies that are primarily focused on developing, researching, and commercializing products related to biotechnology. These stocks are often known for their potential for rapid growth and volatility, as they are often influenced by factors such as clinical trial results, regulatory approvals, and market demand for innovative medical treatments. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of Danaher stock traded down $1.61 during trading on Tuesday, hitting $212.65. The company’s stock had a trading volume of 3,010,344 shares, compared to its average volume of 3,736,368. The stock has a market cap of $153.59 billion, a price-to-earnings ratio of 40.25, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. Danaher has a 52 week low of $210.04 and a 52 week high of $281.70. The stock has a 50-day moving average price of $234.93 and a two-hundred day moving average price of $252.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded up $0.28 on Tuesday, hitting $190.42. The stock had a trading volume of 2,365,998 shares, compared to its average volume of 6,196,291. The stock has a market cap of $336.50 billion, a price-to-earnings ratio of 79.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. AbbVie has a 12-month low of $153.58 and a 12-month high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The business has a 50 day moving average of $176.84 and a 200 day moving average of $185.26.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of MRNA stock traded down $0.82 during trading on Tuesday, reaching $35.73. 12,427,464 shares of the company’s stock traded hands, compared to its average volume of 12,594,480. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $13.75 billion, a P/E ratio of -6.14 and a beta of 1.59. Moderna has a 1 year low of $31.94 and a 1 year high of $170.47. The firm’s 50-day moving average is $40.89 and its 200 day moving average is $60.43.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded down $9.67 during trading hours on Tuesday, hitting $584.09. 663,759 shares of the company’s stock were exchanged, compared to its average volume of 2,047,357. The company has a market capitalization of $223.41 billion, a PE ratio of 35.33, a PEG ratio of 4.06 and a beta of 0.77. The business’s 50 day simple moving average is $542.95 and its 200-day simple moving average is $571.55. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 12-month low of $493.30 and a 12-month high of $627.88.

Fabrinet (FN)

Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services in North America, the Asia-Pacific, and Europe. The company offers a range of advanced optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, advanced packaging, integration, final assembly, and testing.

Fabrinet stock traded down $20.59 during mid-day trading on Tuesday, hitting $205.01. The company had a trading volume of 1,405,910 shares, compared to its average volume of 660,268. The company has a market capitalization of $7.44 billion, a PE ratio of 24.27 and a beta of 0.92. Fabrinet has a 12 month low of $159.69 and a 12 month high of $281.79. The stock’s 50 day moving average price is $231.04 and its two-hundred day moving average price is $234.45.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ VRTX traded up $9.14 during midday trading on Tuesday, hitting $479.51. 543,429 shares of the stock traded hands, compared to its average volume of 1,562,567. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The firm has a 50-day moving average of $434.73 and a two-hundred day moving average of $462.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a market capitalization of $123.49 billion, a P/E ratio of -240.70, a PEG ratio of 2.39 and a beta of 0.41.

Illumina (ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Shares of NASDAQ:ILMN traded down $8.02 during trading on Tuesday, hitting $123.08. 2,056,671 shares of the company’s stock were exchanged, compared to its average volume of 1,676,590. The company has a market cap of $19.52 billion, a price-to-earnings ratio of -12.34 and a beta of 1.10. The business’s 50-day simple moving average is $138.57 and its 200 day simple moving average is $135.43. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66.